ASN003

ASN003 is a novel, highly selective small molecule inhibitor that targets both the BRAF (specifically BRAFV600 mutants) and phosphoinositide 3-kinase (PI3K) pathways. It potently inhibits BRAF, PI3K-alpha, and PI3K-delta isoforms with low affinity for PI3K-beta. ASN003 is designed to address cancers driven by mutations in these pathways, including those resistant to current BRAF or MEK inhibitors. Preclinical studies demonstrated strong antiproliferative activity in cell lines and significant tumor growth inhibition in xenograft models harboring BRAF and PIK3CA or PTEN mutations. Clinical trials are ongoing for advanced solid tumors such as melanoma, colorectal cancer (CRC), and non-small cell lung cancer (NSCLC) with relevant pathway alterations[1][2][5][7].